<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular endothelial growth factor (VEGF(165)) is a potent angiogenic <z:chebi fb="0" ids="52290">mitogen</z:chebi> commonly overexpressed in cancerous cells </plain></SENT>
<SENT sid="1" pm="."><plain>It contains two main binding domains, the receptor-binding domain (RBD) and the <z:chebi fb="5" ids="28304">heparin</z:chebi>-binding domain (HBD) </plain></SENT>
<SENT sid="2" pm="."><plain>This study attempted to identify the specific sequences of the VEa5 DNA aptamer that exhibit high binding affinity towards the VEGF(165) protein by truncating the original VEa5 aptamer into different segments </plain></SENT>
<SENT sid="3" pm="."><plain>Using surface plasmon resonance (SPR) spectroscopy for binding affinity analysis, one of the truncated aptamers showed a &gt;200-fold increase in the binding affinity for HBD </plain></SENT>
<SENT sid="4" pm="."><plain>This truncated aptamer also exhibited high specificity to HBD with negligible binding affinity for VEGF(121), an isoform of VEGF lacking HBD </plain></SENT>
<SENT sid="5" pm="."><plain>Exposing <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells to the truncated aptamer sequence further confirmed the binding affinity and specificity of the aptamer to the target VEGF(165) protein </plain></SENT>
<SENT sid="6" pm="."><plain>Hence, our approach of aptamer truncation can potentially be useful in identifying high affinity aptamer sequences for the biological molecules and targeting them as <z:chebi fb="68" ids="48706">antagonist</z:chebi> for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell detection </plain></SENT>
</text></document>